Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Average Rating of “Moderate Buy” from Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) has been assigned an average rating of “Moderate Buy” from the fifteen analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $203.69.

Several research firms have issued reports on JAZZ. BMO Capital Markets lifted their price target on Jazz Pharmaceuticals from $185.00 to $188.00 and gave the company an “outperform” rating in a research note on Thursday, August 4th. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $174.00 to $187.00 and gave the company an “equal weight” rating in a report on Thursday, August 4th. HC Wainwright decreased their price objective on Jazz Pharmaceuticals from $210.00 to $204.00 in a report on Friday, August 5th. SVB Leerink raised their price objective on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an “outperform” rating in a report on Thursday, August 4th. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 7,703 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $153.18, for a total transaction of $1,179,945.54. Following the completion of the transaction, the chief executive officer now owns 353,311 shares in the company, valued at $54,120,178.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO Patricia Carr sold 2,142 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $160.06, for a total transaction of $342,848.52. Following the completion of the sale, the chief accounting officer now owns 5,934 shares in the company, valued at $949,796.04. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 7,703 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $153.18, for a total value of $1,179,945.54. Following the sale, the chief executive officer now owns 353,311 shares of the company’s stock, valued at approximately $54,120,178.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,764 shares of company stock worth $7,619,938. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Royal London Asset Management Ltd. boosted its holdings in shares of Jazz Pharmaceuticals by 0.5% during the second quarter. Royal London Asset Management Ltd. now owns 21,235 shares of the specialty pharmaceutical company’s stock worth $3,314,000 after acquiring an additional 116 shares during the period. Walleye Capital LLC raised its position in shares of Jazz Pharmaceuticals by 161.7% in the second quarter. Walleye Capital LLC now owns 18,326 shares of the specialty pharmaceutical company’s stock valued at $2,859,000 after buying an additional 11,323 shares in the last quarter. First Republic Investment Management Inc. raised its position in shares of Jazz Pharmaceuticals by 1.5% in the second quarter. First Republic Investment Management Inc. now owns 12,157 shares of the specialty pharmaceutical company’s stock valued at $1,897,000 after buying an additional 184 shares in the last quarter. Captrust Financial Advisors raised its position in shares of Jazz Pharmaceuticals by 32.1% in the second quarter. Captrust Financial Advisors now owns 4,898 shares of the specialty pharmaceutical company’s stock valued at $764,000 after buying an additional 1,191 shares in the last quarter. Finally, Kingsview Wealth Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $241,000. Institutional investors own 92.79% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $152.66 on Tuesday. The business’s 50-day moving average price is $156.08 and its two-hundred day moving average price is $154.64. Jazz Pharmaceuticals has a 1 year low of $117.64 and a 1 year high of $169.98. The company has a market capitalization of $9.53 billion, a price-to-earnings ratio of -179.60, a P/E/G ratio of 1.28 and a beta of 0.68. The company has a debt-to-equity ratio of 1.87, a current ratio of 3.67 and a quick ratio of 2.45.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Recommended Stories

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.